Immuneering (IMRX) Other Non-Current Assets (2020 - 2026)
Immuneering (IMRX) posted quarterly Other Non-Current Assets of $278129.0 for Q1 2026, down 65.7% year-over-year from $810895.0 in Q1 2025, and down 1.92% quarter-over-quarter from $283562.0 in Q4 2025.
Immuneering (IMRX) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Immuneering's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $278129.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 65.7% year-over-year to $278129.0; the TTM figure through Mar 2026 stood at $278129.0 (down 65.7% YoY), while the FY2025 annual figure was $283562.0, down 78.12% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $278129.0, down from $283562.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.3 million in Q4 2024, with the low at $89579.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $743703.0 (2022), against an average of $753538.4.
- Peak annual rise in Other Non-Current Assets reached 5044.02% in 2022, while the deepest fall reached 90.67% in 2022.
- Immuneering's Other Non-Current Assets stood at $743703.0 in 2022, then soared by 39.09% to $1.0 million in 2023, then advanced by 25.26% to $1.3 million in 2024, then slumped by 78.12% to $283562.0 in 2025, then fell by 1.92% to $278129.0 in 2026.
- Business Quant data shows IMRX's Other Non-Current Assets at $278129.0 in Q1 2026, $283562.0 in Q4 2025, and $631297.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 278,124.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 278,124.00 |
| Mar 31, 2026 | 278,129.00 |
| Dec 31, 2025 | 283,562.00 |
| Sep 30, 2025 | 631,297.00 |
| Jun 30, 2025 | 841,726.00 |
| Mar 31, 2025 | 810,895.00 |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Sep 30, 2023 | 743,703.00 |
| Jun 30, 2023 | 743,703.00 |
| Mar 31, 2023 | 743,703.00 |
| Dec 31, 2022 | 743,703.00 |
| Sep 30, 2022 | 737,293.00 |
| Jun 30, 2022 | 89,579.00 |
| Mar 31, 2022 | 89,579.00 |
| Dec 31, 2021 | 102,129.00 |
| Sep 30, 2021 | 14,333.00 |